Twelve Veterans Had Already Failed Every PTSD Treatment. Nine Are in Remission After Two Doses of Psilocybin.

Zachariah Collett spent years living inside what he later called “the internal struggle, the internal dialogue, the noise inside my head and the inability even to just be still.” The Ohio soldier did a 28-month combat tour in Iraq, came home to nightmares and a hair-trigger temper, and was medically retired at 25 with PTSD among his service-connected conditions. He’d already been through the standard menu — medication, prolonged exposure therapy, EMDR — years of it, with little to show for it.

Nine of twelve veterans in a trial built for people exactly like Collett no longer met the clinical criteria for PTSD one month after two doses of psilocybin.

That’s the finding Ohio State University published July 30 in Communications Medicine, and it needs reading in both directions — as real signal, and as a result nowhere near a finished treatment. “Treatment-resistant” isn’t a euphemism here. It means these twelve people had already tried the drugs and therapies that work for most people with PTSD, and none of it moved the noise — a failure that shows up as blown marriages and jobs people can’t hold, not as a diagnostic footnote.

The protocol: eight hours of psychotherapy to prepare, two synthetic psilocybin sessions — 15mg, then 25mg two to three weeks later — then six to eight hours of integration therapy, talk sessions to help someone process what surfaced during dosing. Eleven weeks, start to finish. Researchers screened more than 3,600 applicants down to twelve — nine men, three women — which tells you how narrow the door was and how much unmet need stands behind it. By the one-month mark, average symptom scores had dropped 27.5 points, and 9 of 12 no longer met diagnostic criteria for the disorder — what researchers call remission, meaning symptoms fell below the clinical threshold, not that the memories disappeared. No serious adverse events, no rise in suicidal ideation — the metric these trials get watched hardest for — and mild headache as the worst most people reported.

“For a population with severe treatment-resistant PTSD, these results are striking,” lead author Stacey Armstrong said, noting this kind of treatment failure routes veterans toward “treatment dropout, long-term disability and elevated suicide risk.” Senior author Alan Davis, who directs Ohio State’s psychedelic research center, made a point worth sitting with: symptom improvement started during the eight hours of prep therapy, before anyone took a dose. “This treatment is more than just a drug,” Davis said. “The drug itself is a catalyst for the deep work that opens a window for people to perhaps access things they wouldn’t be able to access emotionally otherwise.”

Nine of twelve is where I land the take: this is real data, and it is not yet a treatment.

Three years out, Collett describes the doses less like a cure than a bridge: “For the first six months to a year, I felt like I had this fantastic set of training wheels while I’m relearning the way to act in situations.” If you’ve sat in a waiting room running through the same worksheet a counselor’s given you three times already, you know what treatment-resistant feels like from the inside — it isn’t stubbornness, it’s biology that didn’t answer what was on the shelf. Collett is one data point. But he’s the reason 75% has a face instead of a decimal.

Twelve people is not a sample you build a treatment guideline on. There was no placebo arm, so some improvement may simply reflect eight hours of psychotherapy and heavy researcher attention — Davis’s comment about pre-dose gains suggests as much. Remission at one month says nothing about remission at six, which is why the team is now seeking — not yet securing — funding for a larger randomized trial with six-month follow-up. Psychedelic medicine has been burned by this optimism before: in 2024 the FDA rejected Lykos Therapeutics’ MDMA-assisted therapy for PTSD over blinding failures that a small open-label pilot hasn’t solved either. Seventy-five percent is worth taking seriously. It is not worth treating as settled.

There was no placebo arm, so some improvement may simply reflect eight hours of psychotherapy and heavy researcher attention — Davis’s comment about pre-dose gains suggests as much.

Money is moving regardless. Texas has committed $50 million to UTHealth Houston and UTMB Health to lead IMPACT — Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma — the largest state-level psychedelic research investment in US history, aimed at veterans and first responders with opioid use disorder and PTSD, with UT Austin and Baylor College of Medicine running a parallel arm on traumatic brain injury. Ibogaine carries real cardiac risk psilocybin doesn’t, but the logic is the same: enough veterans have gone through years of standard care without relief that legislatures are funding the alternative at a scale grants alone can’t reach.

None of that replaces what happens outside a dosing session. A July study out of UNSW, led by social psychologist Prof. Loren Brener in the International Journal of Drug Policy, interviewed 36 workers across drug, alcohol, and mental health services and found peer workers — staff with their own recovery history — do something credentialed clinicians structurally can’t: clients recognize them without being told. “They just know,” Brener said. “They can identify the people who have that real depth of understanding.” That recognition buys trust, and for someone who’s spent years being managed rather than met, proof that a different life is actually livable.

It costs the workers something, too. Brener’s interviews describe peer staff triggered by clients whose histories mirror their own, colleagues who mistake ordinary exhaustion for relapse, and organizations that hand out the title without disclosure guidance or real supervision. “Lived and living experience is a skill and an expertise,” Brener said. “It should be valued that way.” Right now, mostly, it isn’t.

Put the three stories side by side and the shape of this moment gets clear: a striking but small number, a $50 million bet on a riskier molecule, and a workforce nobody funds properly to do the work after week eleven. Psilocybin may move the needle this pilot suggests — the RCT will say more than a 12-person study ever could. But staying in remission, past the one-month mark, still runs through people, not protocols.